Show simple item record

Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases

dc.contributor.authorMorimoto, Chikaoen_US
dc.contributor.authorRomain, Paul L.en_US
dc.contributor.authorFox, David A.en_US
dc.contributor.authorAnderson, Paulen_US
dc.contributor.authorDimaggio, Marjorieen_US
dc.contributor.authorLevine, Herberten_US
dc.contributor.authorSchlossman, Stuart F.en_US
dc.date.accessioned2006-04-07T20:20:00Z
dc.date.available2006-04-07T20:20:00Z
dc.date.issued1988-05en_US
dc.identifier.citationMorimoto, Chikao, Romain, Paul L., Fox, David A., Anderson, Paul, Dimaggio, Marjorie, Levine, Herbert, Schlossman, Stuart F. (1988/05)."Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases." The American Journal of Medicine 84(5): 817-825. <http://hdl.handle.net/2027.42/27324>en_US
dc.identifier.urihttp://www.sciencedirect.com/science/article/B6TDC-4CHHJJF-GB/2/6e989a1848032468473e51a74b654659en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/27324
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=2966579&dopt=citationen_US
dc.description.abstractThe monoclonal antibodies anti-2H4 and anti-4B4 identify the suppressor-inducer (CD4+2H4+) and helper-inducer (CD4+4B4+) subpopulations of CD4 (T4+) lymphocytes, respectively. The cell surface phenotype of peripheral blood lymphocytes and synovial fluid lymphocytes in patients with rheumatoid arthritis and other inflammatory joint diseases was analyzed by use of these and other well-characterized anti-T-cell monoclonal antibodies. In the synovial fluid of patients with rheumatoid arthritis, there was a markedly decreased percentage of T4+2H4+ suppressor-inducer cells (3.1 +/- 1 percent) and an increased percentage of T4+4B4+ helper-inducer cells (29.1 +/- 9 percent) as compared with the proportions found in the peripheral blood of normal individuals (T4+2H4+: 19.0 +/- 6 percent, T4+4B4+: 23.0 +/- 7 percent). Moreover, patients with other chronic and acute inflammatory joint diseases exhibited highly similar synovial T-cell findings to those of the patients with rheumatoid arthritis (T4+2H4+: 4.2 +/- 3 percent, T4+4B4+: 33.1 +/- 9 percent). In contrast, there were no significant differences between the normal control subjects and patients with rheumatoid arthritis in the percentage of T4+2H4+ cells in peripheral blood lymphocytes, nor were there significant differences between normal control subjects, patients with rheumatoid arthritis, and patients with other joint diseases (osteoarthritis, gout, B27+ spondyloarthropathy, and psoriatic arthritis) in the number of T4+4B4+ cells or in the T4/T8 ratio of peripheral blood lymphocytes. However, very low numbers of T4+2H4+ (suppressor-inducer) peripheral blood lymphocytes were seen in a subgroup of patients, including five of seven with Reiter's syndrome and several patients with systemic rheumatic disease syndromes. In addition, although the percentage of T4+2H4+ cells in peripheral blood lymphocytes of patients with osteoarthritis (13.7 +/- 7 percent) and gout (14.3 +/- 7 percent) was decreased compared with that of normal controls (19.0 +/- 6 percent) (osteoarthritis versus normal controls p &lt;0.025), this difference appeared to reflect alterations due to age rather than disease. Consistent with the phenotypic changes observed, synovial T cells were also functionally defective, since autologous mixed lymphocyte reaction-activated T4 cells from the synovial fluid of patients with rheumatoid arthritis failed to exhibit suppressor-inducer activity. The results indicate that diminished proportions of CD4+2H4+ (suppressor-inducer) cells and increased proportions of CD4+4B4+ (helper) cells are a common feature of CD4+ cells in synovial fluid in rheumatoid arthritis as well as a variety of other inflammatory disorders, whereas modest changes in CD4+2H4+ peripheral blood lymphocytes are seen in older individuals and more marked decreases are observed only in a more selected group of patients. These changes may be of potential functional importance in the regulation of the immune response in a variety of clinical settings.en_US
dc.format.extent1122412 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherElsevieren_US
dc.titleAbnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseasesen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelFamily Medicine and Primary Careen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Internal Medicine, Division of Rheumatology and Rackham Arthritis Research Unit, University of Michigan Medical Center, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationotherDivision of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, and the Department of Medicine, Division of Rheumatology/Immunology, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USAen_US
dc.contributor.affiliationotherDivision of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, and the Department of Medicine, Division of Rheumatology/Immunology, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USAen_US
dc.contributor.affiliationotherDivision of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, and the Department of Medicine, Division of Rheumatology/Immunology, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USAen_US
dc.contributor.affiliationotherDivision of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, and the Department of Medicine, Division of Rheumatology/Immunology, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USAen_US
dc.contributor.affiliationotherDivision of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, and the Department of Medicine, Division of Rheumatology/Immunology, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USAen_US
dc.contributor.affiliationotherDivision of Tumor Immunology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, and the Department of Medicine, Division of Rheumatology/Immunology, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USAen_US
dc.identifier.pmid2966579en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/27324/1/0000347.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1016/0002-9343(88)90058-7en_US
dc.identifier.sourceThe American Journal of Medicineen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.